<div id="readability-page-1"><div>By Connor Hart Genentech, a member of the Roche Group, said the U.S. Food and Drug Administration approved its treatment for follicular lymphoma. The therapy, Lunsumio VELO, can be used to treat adult patients with relapsed or refractory follicular lymphoma, a type of cancer of the lymphatic system, following two or more lines of systemic therapy, the company said Monday. Lunsumio VELO reduces administration time with an approximately one-minute injection, compared with an intravenous infusion of up to four hours, according to Genentech. &#34;With this FDA approval, treatment can now be administered in just one minute, which significantly reduces the time patients spend in the clinic and helps to align care with their individual needs and preferences,&#34; Levi Garraway, chief medical officer and head of global product development, said. Lunsumio VELO's approval is based on the primary analysis of a recent study, in which patients receiving the treatment showed a 75% objective response rate and a 59% complete response rate, Genentech said. Write to Connor Hart at connor.hart@wsj.com (END) Dow Jones Newswires12-22-25 0739ET</div></div>

罗氏(ADR)

基因泰克（Genentech），罗氏集团的一部分，已获得 FDA 对 Lunsumio VELO 的批准，该药物用于治疗复发性或难治性滤泡性淋巴瘤。这种疗法显著缩短了给药时间，仅需一分钟注射，而不是四小时的输注。该批准基于一项研究，显示出 75% 的客观反应率和 59% 的完全反应率。这一进展符合患者对更高效治疗选择的需求

基因泰克获得 FDA 批准用于淋巴瘤治疗